Events
Navigating a Path to Advance the Use of Liquid Biopsies for Early Cancer Screening and Detection (Panel Discussion)
In this event at the Festival of Genomics and Biodata, BLOODPAC members will discuss current progress and clinical advances in liquid biopsy for early cancer detection, and current challenges and opportunities in multi-cancer early detection testing and MRD testing/patient monitoring. Panelists include Jonathan Beer (Senior Director of Diagnostic Sciences, Bristol Meyers Squibb), Lauren Leiman (Executive Director, BLOODPAC), and Carl Barrett (VP Translational Sciences--Oncology, AztraZeneca).
Creating Consensus on a Lexicon, Standards, and Frameworks for Multi-Cancer Detection (Talk)
Stakeholder collaboration is critical for advancing the development and clinical implementation of multi-cancer early detection and screening. In this talk at the Next Generation Dx 2023 Conference, BLOODPAC’s Executive Director will discuss the efforts BLOODPAC has launched related to standards and framework development, education, and access coordination for MCED. The vision of BLOODPAC’s Screening and Early Detection Working Group includes:
(1) thinking creatively about how best to evaluate the impact of early detection strategies on morbidity and mortality resulting from rare and currently unscreened cancers
(2) engaging providers and patients in understanding and mitigating the barriers to implementation of blood-based cancer screening tests and provide recommendations for an equitable, resilient, and sustainable healthcare ecosystem that benefits people
(3) engaging and collaborating with regulatory agencies to generate postmarket evidence to support the safety and effectiveness of blood-based cancer screening tests in real-world use.
In this session, we will discuss progress to date on these initiatives, including our soon-to-be-published lexicon of standard terms for blood-based assays for the screening and early detection of cancer.
Panel Discussion on ctDNA for Solid Tumor Drug Development
This AACR23 session will update the cancer research community on the FDA guidance and other various efforts from multiple stakeholders on the use of liquid biopsies in early-stage, solid tumor drug development. Jonathan Baden (Bristol Myers Squibb), co-chair of BLOODPAC's Analytical Validation working group, will be representing BLOODPAC on the panel.
Standardizing Frameworks and Democratizing Access to Liquid Biopsy (Talk)
In this talk, BLOODPAC's Executive Director will discuss the organization's progress in:
(1) Educating the liquid biopsy community on evidence-based clinical utility and healthcare satisfaction
(2) Democratizing access to tests to improve patient outcomes
(3) Adopting liquid biopsy access approaches through the improvement of frameworks for access
(4) Evalutating the use of current regulation for adequate ctDNA access.
Focused Ultrasound and Liquid Biopsy - 2022 Symposium
Hosted by The Focused Ultrasound Foundation
Non-Small Cell Lung Cancer Drug Development Summit
The 2nd NSCLC Drug Development Summit is the only industry-led forum for large bio-pharma, biotech, and academic leaders to address mechanisms of drug resistance, spearhead progress in molecular subtyping, and define practice-changing drug sequencing and combinations for the largest solid tumor indication.
